Caroline Helwick
Tycel Phillips, MD, discusses a phase 1/2 trial combining subcutaneous epcoritamab with rituximab and lenalidomide in patients with relapsed or refractory follicular lymphoma, as presented at the 63rd ASH Annual Meeting in 2021.
In this explorative study, we aimed to investigate the baseline PET/CT radiomics features in combination with clinical risk factors to predict the interim treatment response of follicular lymphoma patients receiving the R-CHOP treatment regimen. This is intended to early identify patients with poor tre...
Dr Maddocks, I think there is 1 subtype situation where I would argue that we should probably not give just R-CHOP, in a patient who actually has double-hit or maybe double-expression lymphoma. Do you want to comment what your experience is in this and recommendation? Kami Maddocks, MD:I...
Diffuse large B cell lymphoma (DLBCL) is a heterogeneous disease treated with anti-CD20-based immuno-chemotherapy (R-CHOP). We identified that low levels of GAPDH predict a poor response to R-CHOP treatment. Importantly, we demonstrated that GAPDHlow lymphomas use OxPhos metabolism and rely on ...
Caroline Helwick
INTRODUCTION The optimal frontline treatment for mantle cell lymphoma (MCL) is not clearly defined. Bendamustine + rituximab (BR) is commonly used as initial therapy. The role of maintenance rituximab (MR) after BR is not agreed upon due to limited data supporting this practice, whereas MR ...
Introduction Despite gains in survival with aggressive upfront treatments, such as R-CHOP ( rituximab , doxorubicin, vincristine, prednisone) for follicular lymphoma (FL), and the implementation of rituximab maintenance, approximately 20% of patients will still experience progression of disease (POD) ...